D4S Stock Overview
Manufactures and sells pharmaceutical products in Japan, North America, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
My Notes
Capture your thoughts, links and company narrative
Daiichi Sankyo Company, Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥24.74 |
| 52 Week High | JP¥37.90 |
| 52 Week Low | JP¥24.02 |
| Beta | 0.26 |
| 1 Month Change | -5.75% |
| 3 Month Change | -15.13% |
| 1 Year Change | -13.95% |
| 3 Year Change | 36.69% |
| 5 Year Change | 12.45% |
| Change since IPO | 404.55% |
Recent News & Updates
Recent updates
Shareholder Returns
| D4S | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -11.1% | -5.2% | 0.5% |
| 1Y | -13.9% | -10.6% | 15.3% |
Return vs Industry: D4S underperformed the German Pharmaceuticals industry which returned -11.7% over the past year.
Return vs Market: D4S underperformed the German Market which returned 13.7% over the past year.
Price Volatility
| D4S volatility | |
|---|---|
| D4S Average Weekly Movement | 6.5% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: D4S has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: D4S's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1899 | 18,726 | Sunao Manabe | www.daiichisankyo.com |
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, North America, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule that targets colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with acute myeloid leukemia; and Injectafer, a ferric carboxymaltose injection to treat iron deficiency. It also provides Liziana and Savaysa, direct factor Xa inhibitors; Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar, and Sevikar HCT antihypertensive agents; Nilemdo, an oral treatment which lowers cholesterol; Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe to reduce cholesterol; and Efient, an anti-platelet agent.
Daiichi Sankyo Company, Limited Fundamentals Summary
| D4S fundamental statistics | |
|---|---|
| Market cap | €45.89b |
| Earnings (TTM) | €1.56b |
| Revenue (TTM) | €11.39b |
29.4x
P/E Ratio4.0x
P/S RatioIs D4S overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| D4S income statement (TTM) | |
|---|---|
| Revenue | JP¥1.80t |
| Cost of Revenue | JP¥426.02b |
| Gross Profit | JP¥1.37t |
| Other Expenses | JP¥1.12t |
| Earnings | JP¥245.77b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 130.80 |
| Gross Margin | 76.28% |
| Net Profit Margin | 13.68% |
| Debt/Equity Ratio | 6.2% |
How did D4S perform over the long term?
See historical performance and comparisonDividends
1.6%
Current Dividend Yield47%
Payout RatioDoes D4S pay a reliable dividends?
See D4S dividend history and benchmarks| Daiichi Sankyo Company dividend dates | |
|---|---|
| Ex Dividend Date | Mar 28 2025 |
| Dividend Pay Date | Jun 18 2025 |
| Days until Ex dividend | 48 days |
| Days until Dividend pay date | 130 days |
Does D4S pay a reliable dividends?
See D4S dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/06 12:32 |
| End of Day Share Price | 2025/02/06 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Daiichi Sankyo Company, Limited is covered by 32 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Atsushi Seki | Barclays |
| null null | BNP Paribas Securities (Asia) |
| Koichi Mamegano | BofA Global Research |